Leo Pharma

To see an up-to date selection of historical analyses and insights on Leo Pharma, visit our new, dynamically updated Company Summary report pages for Leo Pharma.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Leo Pharma are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Leo Pharma, or on any other Company covered by EvaluatePharma® Contact Us today.

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
 
  Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current)
Leo Pharma - CB1089 Oncology & Immunomodulators Other cytostatics Vitamin D analogue Phase I
  - Oxygent Blood Blood substitutes Perfluorocarbon-based oxygen carrier Phase II
  - LEO 80190 Dermatology Anti-psoriasis agents Vitamin D analogue Phase III

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
Leo Pharma
  2005 2006
 Valuation Measures
  Based on Latest Share Prices
     Valuing the Equity
 
     Valuing the Enterprise
 
 Forecast Financials
  Income Statement
     Total Revenues 811 872
     R&D (138) (148)
     Other Income/ Expense - Net (385) (216)
     EBIT - Normalised 288 508
     Net Interest & Financial Items 132 -
     Pre-tax Profits - Normalised 419 508
     Income Before Taxes 419 508
     Tax (91) (98)
     Tax Rate (%) 21.7% 19.4%
     Net Income - Reported 328 410
     Net Income - Normalised 328 410
 
  Per Share Data
     EPS - Diluted 3.28 4.10
     EPS - Basic 3.28 4.10
     EPS - Normalised (diluted) 3.28 4.10
     EPS - Normalised (basic) 3.28 4.10
     Avg. Shares Outstanding - Diluted 100.0 100.0
     Avg. Shares Outstanding - Basic 100.0 100.0
     DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)
LEO Pharma Establishes Strategic Company in China   (Leo Pharma)   08-Dec-2008
Xamiol® – LEO Pharma’s New Drug for the Treatment of Scalp Psoriasis Launched in Europe   (Leo Pharma)   03-Nov-2008
FDA Assigns Priority Review to GTC Biotherapeutics’ ATryn®   (GTC Biotherapeutics)   04-Sep-2008
Xamiol® – a New Drug for the Treatment of Scalp Psoriasis is Approved in Europe   (Leo Pharma)   19-Aug-2008
FDA Approves Taclonex Scalp®   (Leo Pharma)   13-May-2008
FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis   (Warner Chilcott)   12-May-2008

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
 
  Product Generic Name
Leo Pharma Atocalcitol atocalcitol
  ATryn antithrombin alfa
  Burinex bumetanide
  Calcipotriene foam calcipotriene
  CB1089 seocalcitol
  Centyl bendroflumethiazide
  CEP-3265 -
  CHS 828 -
  Coactin/Selexidin mecillinam (amdinocillin)
  Daivonex calcipotriene
  Duac/Clindoxyl clindamycin & benzoyl peroxide
  EB 1627 -
  EO1606 -
  Fucicort fusidic acid & betamethasone valerate
  Fucidin fusidic acid
  Fucidin H fusidic acid & hydrocortisone
  Fucithalmic fusidic acid
  GD4040 -
  GH9001 -
  GMX1777 -
  Heparin LEO heparin
  HL10 -
  Innohep tinzaparin
  Kaleorid potassium chloride
  LEO 15520 -
  LEO 19123 -
  LEO 80140 -
  LEO 80190 calcipotriol & hydrocortisone
  Malvitona vitamin B & caffeine
  One-Alpha alfacalcidol
  Oxygent perflubron
  Pindac pinacidil
  Pondocillin pivampicillin
  Protamine sulfate protamine sulfate
  PXD118490 -
  Selexid pivmecillinam
  SWITCH collaboration -
  Taclonex calcipotriene & betamethasone
  Taclonex Scalp calcipotriene & betamethasone
  TD 1414 -

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.